Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Sunhee Kim  (Kim S) 2 Articles
Clinical Study
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinol Metab. 2021;36(2):388-400.   Published online March 31, 2021
DOI: https://doi.org/10.3803/EnM.2020.912
  • 4,120 View
  • 301 Download
  • 9 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.
Methods
We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.
Results
Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.
Conclusion
SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.

Citations

Citations to this article as recorded by  
  • New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist
    Pavel Weber, Hana Meluzínová, Dana Weberová
    Klinická farmakologie a farmacie.2022; 35(4): 118.     CrossRef
  • Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
    Hongwei Cao, Tao Liu, Li Wang, Qiuhe Ji
    Diabetes, Obesity and Metabolism.2022; 24(8): 1448.     CrossRef
  • Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
    Die Diabetologie.2022; 18(5): 623.     CrossRef
  • Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An obser
    Iskandar Idris, Ruiqi Zhang, Jil B. Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
    Diabetes, Obesity and Metabolism.2022; 24(11): 2138.     CrossRef
  • Therapy of Type 2 Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
    Experimental and Clinical Endocrinology & Diabetes.2022; 130(S 01): S80.     CrossRef
  • Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
    Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
    Molecules.2022; 27(19): 6221.     CrossRef
  • Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
    Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
    Rheumatology.2022;[Epub]     CrossRef
  • New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
    Chan-Hee Jung
    Endocrinology and Metabolism.2021; 36(2): 339.     CrossRef
  • Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
    André J. Scheen
    Diabetes & Metabolism.2021; 47(6): 101275.     CrossRef
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinol Metab. 2019;34(1):80-92.   Published online March 21, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.80
  • 5,081 View
  • 208 Download
  • 31 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background

To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.

Methods

MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome.

Results

We included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P<0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, −1.11 mL/min/1.73 m2; 95% CI, −1.78 to −0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475).

Conclusion

DPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.

Citations

Citations to this article as recorded by  
  • Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
    Edoardo Mannucci, Marco Gallo, Andrea Giaccari, Riccardo Candido, Basilio Pintaudi, Giovanni Targher, Matteo Monami
    Diabetes, Obesity and Metabolism.2023; 25(2): 444.     CrossRef
  • Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
    Christian W. Mende
    Advances in Therapy.2022; 39(1): 148.     CrossRef
  • Management of Hyperglycemia in Older Adults with Type 2 Diabetes
    Gunjan Y. Gandhi, Arshag D. Mooradian
    Drugs & Aging.2022; 39(1): 39.     CrossRef
  • Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
    Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
    Expert Review of Pharmacoeconomics & Outcomes Research.2022; : 1.     CrossRef
  • Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
    Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685.     CrossRef
  • Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
    Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
    The Korean Journal of Internal Medicine.2022; 37(3): 502.     CrossRef
  • The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
    Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
    Journal of Clinical Medicine.2022; 11(9): 2653.     CrossRef
  • Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
    Hiroaki Yagyu, Hitoshi Shimano
    Journal of Diabetes Investigation.2022; 13(9): 1472.     CrossRef
  • Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
    Ayesha Abdul Qadir Memon, Sarmad Iqbal
    Global Journal of Medical, Pharmaceutical, and Biomedical Update.2022; 17: 12.     CrossRef
  • The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
    Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
    Diabetes, Obesity and Metabolism.2021; 23(3): 763.     CrossRef
  • Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
    Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
    American Journal of Physiology-Renal Physiology.2021; 320(3): F285.     CrossRef
  • Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Johannes F.E. Mann, Marcel H.A. Muskiet
    Kidney International.2021; 99(2): 314.     CrossRef
  • Renoprotective Effects of DPP-4 Inhibitors
    Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
    Antioxidants.2021; 10(2): 246.     CrossRef
  • Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
    Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
    International Journal of Molecular Sciences.2021; 22(6): 2809.     CrossRef
  • Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Endocrinology and Metabolism.2021; 36(2): 388.     CrossRef
  • Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
    European Cardiology Review.2021;[Epub]     CrossRef
  • Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
    Metabolism.2021; 120: 154799.     CrossRef
  • SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
    Robert C. Stanton
    Seminars in Nephrology.2021; 41(2): 85.     CrossRef
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
    Pharmaceuticals.2021; 14(6): 561.     CrossRef
  • Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
    Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
    Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
    Pharmaceuticals.2021; 14(8): 751.     CrossRef
  • Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
    SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
    Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283.     CrossRef
  • Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
    Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
    Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
    Pharmacophore.2021; 12(3): 91.     CrossRef
  • Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
    Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
    Hormones.2020; 19(4): 467.     CrossRef
  • Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams, Asif Nawaz, Marc Evans
    Diabetes Therapy.2020; 11(2): 369.     CrossRef
  • Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
    Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Novel therapeutic agents for the treatment of diabetic kidney disease
    Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
    Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
  • Renal protection with glucagon-like peptide-1 receptor agonists
    Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
    Current Opinion in Pharmacology.2020; 54: 91.     CrossRef
  • Loss of Mitochondrial Control Impacts Renal Health
    Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Scientific Reports.2019;[Epub]     CrossRef

Endocrinol Metab : Endocrinology and Metabolism